Main menu


Moderna seeks European approval for its vaccine for children from 12 years of age

Moderna has requested approval from European Union regulators to use its COVID-19 vaccine on children from 12 years of age, as vaccine rollouts expand to younger populations.

The American pharmaceutical company stated - in a statement reported on its official website today, Monday - that it had applied to the European Medicines Agency for a license to use its vaccine in children aged 12 to 18 years, after clinical trials showed its 100% effectiveness.

Moderna is the second pharmaceutical company seeking to expand the use of its vaccine in the European Union, after the American "Pfizer" and its German partner, "Biontech", obtained approval to use their vaccine for children last May. Both vaccines are based on mRNA technology.

Moderna said it has also applied for a license in Canada, and will submit its data to US regulators soon as well.

"We remain committed to doing our part to help end the COVID-19 pandemic," CEO Stefan Bancel said in a statement.